Genemige < 2024-2026 >

In 2000, Genmab entered into a collaboration with GlaxoSmithKline (GSK) to develop a therapeutic antibody for the treatment of rheumatoid arthritis. This partnership led to the development of the antibody, known as HuMax-CD20, which was later approved by the US FDA under the brand name Ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia (CLL).